We are live on ! Find out more
JJIJ

Johnson & Johnson Innovation - JJDC Portfolio holdings

AUM $978M
1-Year Est. Return 102.17%
This Fund
S&P 500
This Quarter Est. Return
+17.66%
1 Year Est. Return
+102.17%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$978M
AUM Growth
+$206M
Cap. Flow
+$109M
Cap. Flow %
11.13%
Top 10 Hldgs %
97.58%
Holding
21
New
4
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
CVRX icon
CVRx
CVRX
+$97.9M
2
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$10.2M
3
NPCE icon
Neuropace
NPCE
+$1.29M
4
ZY
Zymergen Inc. Common Stock
ZY
+$653K

Top Sells

Rank Stock Value
1
SENS icon
Senseonics Holdings Inc
SENS
+$1.11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.78%
2 Technology 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
1
Fate Therapeutics
FATE
$318M
$293M 29.98%
3,379,064
– –
ARWR icon
2
Arrowhead Research
ARWR
$10.1B
$270M 27.61%
3,260,869
– –
PTGX icon
3
Protagonist Therapeutics
PTGX
$8.49B
$110M 11.24%
2,449,183
– –
CVRX icon
4
CVRx
CVRX
$143M
$97.9M 10.01%
+3,495,575
New +$97.9M
LEGN icon
5
Legend Biotech
LEGN
$4.39B
$66.9M 6.84%
1,629,173
– –
MGTX icon
6
MeiraGTx Holdings
MGTX
$1.14B
$44.9M 4.59%
2,898,550
– –
FUSN
7
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$29.7M 3.03%
3,670,516
– –
VOR icon
8
Vor Biopharma
VOR
$940M
$20M 2.05%
53,733
– –
PHGE icon
9
BiomX
PHGE
$2.23M
$11.6M 1.19%
11,228
– –
PNT
10
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$10.3M 1.05%
+1,000,000
New +$10.2M
ACET icon
11
Adicet Bio
ACET
$76.8M
$7.5M 0.77%
45,559
– –
PHAS
12
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$5.98M 0.61%
1,607,044
– –
ALDX icon
13
Aldeyra Therapeutics
ALDX
$104M
$4.47M 0.46%
394,834
– –
CSLT
14
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$2.13M 0.22%
811,295
– –
NPCE icon
15
Neuropace
NPCE
$562M
$1.32M 0.13%
+55,435
New +$1.29M
ZY
16
DELISTED
Zymergen Inc. Common Stock
ZY
$662K 0.07%
+16,553
New +$653K
TCON
17
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$545K 0.06%
4,200
– –
GYRE icon
18
Gyre Therapeutics
GYRE
$716M
$290K 0.03%
8,927
– –
CALC icon
19
CalciMedica
CALC
$11M
$269K 0.03%
3,539
– –
LUNG icon
20
Pulmonx
LUNG
$61.2M
$249K 0.03%
5,639
– –
SENS icon
21
Senseonics Holdings Inc
SENS
$268M
$210K 0.02%
2,731
-21,882
-89% -$1.11M

Similar funds

NNP
Nachman Norwood & Parrott Greenville, South Carolina $984M AUM 33.8% 1-Year Est. Return
BAWC
Black-and-white Capital Los Angeles, California $967M AUM 94.03% 1-Year Est. Return
RP
RR Partners New York $929M AUM 110.28% 1-Year Est. Return
NIA
Northstar Investment Advisors Denver, Colorado $755M AUM 37.8% 1-Year Est. Return
SCM
Snow Capital Management Sewickley, Pennsylvania $703M AUM 76.26% 1-Year Est. Return
EMG
Ellington Management Group Old Greenwich, Connecticut $676M AUM 23.65% 1-Year Est. Return
APA
Allegiant Private Advisors Sarasota, Florida $618M AUM
HFA
Hoover Financial Advisors Malvern, Pennsylvania $562M AUM 37.9% 1-Year Est. Return

Johnson & Johnson Innovation - JJDC's Q2 2021 Portfolio in Review

As of Q2 2021, Johnson & Johnson Innovation - JJDC held 21 positions worth $978M, up 27% from $772M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Johnson & Johnson Innovation - JJDC deployed $109M of net new capital in Q2 2021, opening 4 new positions. Its largest new stake was CVRx: 3,495,575 shares worth $97.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Senseonics Holdings Inc, an estimated $1.11M trimmed.

  • Johnson & Johnson Innovation - JJDC's largest Q2 2021 buy was CVRx: 3,495,575 shares worth $97.9M.
  • Johnson & Johnson Innovation - JJDC's biggest Q2 2021 reduction was Senseonics Holdings Inc, cutting an estimated $1.11M.
  • Johnson & Johnson Innovation - JJDC's ten largest holdings make up 98% of its $978M portfolio in Q2 2021.
  • Johnson & Johnson Innovation - JJDC opened 4 new positions and closed 0 in Q2 2021.
  • Johnson & Johnson Innovation - JJDC's portfolio value rose 27% quarter-over-quarter to $978M.

Based on Johnson & Johnson Innovation - JJDC's 13F filing for Q2 2021, filed 3 Aug 2021.